Digital Tools and Glucose Monitoring for Adults With Type 2 Diabetes
Tests a glucose sensor and mobile apps in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Digital Health Solutions for Patients With Type 2 Diabetes
Key facts
- Where
- Taoyuan, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 75 years old?
Source: NCT07642830, who can take part
Where in Taiwan
- Chang Gung Memorial HospitalTaoyuan, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung Memorial Hospital
- Trial code
- NCT07642830
- Record updated
- 11 June 2026
- Original description
We will conduct a prospective, single-center observational study involving 60 adult T2D patients recruited from Chang Gung Memorial Hospital. Participants will be randomly allocated to either a CGM group or a control group receiving standard care. The intervention group will utilize mobile apps for medication tracking, and a remote communication platform. All participants will collect clinical data-including HbA1c, Time in Range (TIR), insulin use-at baseline and 12 weeks. Patient adherence and satisfaction with CGM will also be assessed.Read full original descriptionShow less
Clinical Research of Digital Health Solutions for Patients With Type 2 Diabetes
We will conduct a prospective, single-center observational study involving 60 adult T2D patients recruited from Chang Gung Memorial Hospital. Participants will be randomly allocated to either a CGM group or a control group receiving standard care. The intervention group will utilize mobile apps for medication tracking, and a remote communication platform. All participants will collect clinical data-including HbA1c, Time in Range (TIR), insulin use-at baseline and 12 weeks. Patient adherence and satisfaction with CGM will also be assessed.
Inclusion: Patients with confirmed diagnosis of T2D for >1 year, capable of using a smartphone, and willing to sign informed consent.
Exclusion: Patients with severe cardiac, hepatic, or renal disease; pregnant women; those participating in other experimental treatments; or unable to follow up.